Skip to content

First-in-Man of Pulmonary artery denervation for treatment of pulmonary artery hypertention: the PADN-1 trial

First-in-Man of Pulmonary artery denervation for treatment of pulmonary artery hypertention: the PADN-1 trial

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-12002085
Enrollment
Unknown
Registered
2012-04-04
Start date
2012-04-20
Completion date
Unknown
Last updated
2017-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary artery hypertension

Interventions

one:pulmonary artery renervation(PADN)

Sponsors

Jiangsu Provincial Outstanding Medical Program
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age=3-month) pulmonary thrombus; 5. pulmonary artery hypertension secondary from Pulmonary fibrosis; 6. pulmonary artery hypertension secondary from cirrhosis; 7. Pulmonary hypertension after surgical cardiac surgery; 8. Mean pulmonary artery pressure>=25 mmHg(Resting), or >=30 mmHg (Exercise); 9. Voluntary acceptance of all follow-up assessment of program requirements.

Exclusion criteria

Exclusion criteria: 1. pulmonary artery hypertension secondary from atrial septal defect, or from ventricular septal defect, or from patent duct artery; 2. Renal dysfunction; 3. Liver dysfunction; 4. Blood platelet count=70%; 6. history of percutaneous coronary intervention or coronary artery bypass graft; 7. Family history of syncope of unknown reasons; 8. Expected life span<12-month; 9. In pregnance; 10. Systematical inflammation; 11. Malignant cancer(s); 12. Tricuspid or pulmonary valve stenosis; 13. Supra-pulmonary valve stenosis; 14. Dianosed deep venous thrombus<3-month; 15. Allergic to studied drugs; 16. Allergic to metal materials; 17. Normal thyroid function; 18. inferior vena cava normal; 19. positive result from adenosine test (defined as a decrease of the mean PAP "10 mm Hg to an absolute level of <40 mm Hg, measured by right heart atheterization).

Design outcomes

Primary

MeasureTime frame
6-min.walking distance;Mean pulmonary artery pressure;Tei index;

Secondary

MeasureTime frame
Systolic pulmonary artery pressure;

Countries

China

Contacts

Public ContactShao-Liang Chen
chmengx@126.com+86 13605157029

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026